AU2020456532B9 - Mannose-based mRNA targeted delivery system and use thereof - Google Patents

Mannose-based mRNA targeted delivery system and use thereof Download PDF

Info

Publication number
AU2020456532B9
AU2020456532B9 AU2020456532A AU2020456532A AU2020456532B9 AU 2020456532 B9 AU2020456532 B9 AU 2020456532B9 AU 2020456532 A AU2020456532 A AU 2020456532A AU 2020456532 A AU2020456532 A AU 2020456532A AU 2020456532 B9 AU2020456532 B9 AU 2020456532B9
Authority
AU
Australia
Prior art keywords
mrna
mannose
guanosine
conjugate
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020456532A
Other languages
English (en)
Other versions
AU2020456532B2 (en
AU2020456532A1 (en
Inventor
Yong Hu
Miaomiao Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Rhegen Biotechnology Co Ltd
Original Assignee
Shenzhen Rhegen Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Rhegen Biotechnology Co Ltd filed Critical Shenzhen Rhegen Biotechnology Co Ltd
Publication of AU2020456532A1 publication Critical patent/AU2020456532A1/en
Assigned to SHENZHEN RHEGEN BIOTECHNOLOGY CO., LTD. reassignment SHENZHEN RHEGEN BIOTECHNOLOGY CO., LTD. Amend patent request/document other than specification (104) Assignors: SHENZHEN RHEGEN BIOMEDICAL TECHNOLOGY CO., LTD.
Application granted granted Critical
Publication of AU2020456532B2 publication Critical patent/AU2020456532B2/en
Publication of AU2020456532B9 publication Critical patent/AU2020456532B9/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • C07H5/06—Aminosugars
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2020456532A 2020-07-01 2020-10-27 Mannose-based mRNA targeted delivery system and use thereof Active AU2020456532B9 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010629898.4A CN111744019B (zh) 2020-07-01 2020-07-01 基于甘露糖的mRNA靶向递送系统及其应用
CN202010629898.4 2020-07-01
PCT/CN2020/123993 WO2022000884A1 (zh) 2020-07-01 2020-10-27 基于甘露糖的mRNA靶向递送系统及其应用

Publications (3)

Publication Number Publication Date
AU2020456532A1 AU2020456532A1 (en) 2022-02-03
AU2020456532B2 AU2020456532B2 (en) 2023-04-27
AU2020456532B9 true AU2020456532B9 (en) 2023-06-29

Family

ID=72678803

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020456532A Active AU2020456532B9 (en) 2020-07-01 2020-10-27 Mannose-based mRNA targeted delivery system and use thereof

Country Status (5)

Country Link
US (2) US11707528B2 (zh)
EP (1) EP4008334A4 (zh)
CN (2) CN111744019B (zh)
AU (1) AU2020456532B9 (zh)
WO (1) WO2022000884A1 (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111041025B (zh) 2019-12-17 2021-06-18 深圳市瑞吉生物科技有限公司 基于结合N-乙酰半乳糖胺多肽的mRNA靶向分子及其制备方法
CN111744019B (zh) 2020-07-01 2023-08-04 深圳瑞吉生物科技有限公司 基于甘露糖的mRNA靶向递送系统及其应用
CN114807154B (zh) * 2020-12-10 2024-05-28 深圳瑞吉生物科技有限公司 一种修饰的核酸及其应用
CN113244412B (zh) * 2021-06-25 2021-10-26 深圳市瑞吉生物科技有限公司 一种基于mRNA剂型的治疗高尿酸血症或痛风的药物及其制备方法
CN113244413B (zh) * 2021-06-28 2021-10-26 深圳市瑞吉生物科技有限公司 一种mRNA剂型的骨关节炎药物制剂及其制备方法和应用
CN115611757A (zh) * 2021-07-16 2023-01-17 江苏慧聚药业股份有限公司 mRNA传递剂的合成
CN114685586A (zh) * 2022-03-05 2022-07-01 武汉瑞佶生物科技有限公司 一种mRNA-脂肪酸靶向化合物及其制备方法和应用
WO2023225660A1 (en) * 2022-05-19 2023-11-23 The Broad Institute, Inc. Reagents and methods for preparing derivatized rna molecules and methods of use thereof
CN115010794A (zh) * 2022-06-30 2022-09-06 武汉瑞佶生物科技有限公司 蛋白质介导的mRNA靶向分子及其制备方法和应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6537749B2 (en) 1998-04-03 2003-03-25 Phylos, Inc. Addressable protein arrays
CN1297907A (zh) 1999-11-24 2001-06-06 上海博容基因开发有限公司 一种新的多肽——人乙酰半乳糖苷转移酶45和编码这种多肽的多核苷酸
CN1347903A (zh) 2000-10-11 2002-05-08 上海博德基因开发有限公司 一种新的多肽——人GalNAc－T9.02和编码这种多肽的多核苷酸
AU2003265523A1 (en) 2002-08-20 2004-03-11 Genitrix, Llc Lectin compositions and methods for modulating an immune response to an antigen
JP2010500967A (ja) 2006-07-20 2010-01-14 ザ ジェネラル ホスピタル コーポレイション コンビナトリアルターゲティングを通じたプロトキシンの選択的活性化のための方法、組成物、およびキット
EP2111237B1 (en) 2006-12-11 2015-03-18 BRACCO IMAGING S.p.A. Fibrin-binding peptides and conjugates thereof
AU2008340355B2 (en) 2007-12-04 2015-01-22 Tekmira Pharmaceuticals Corporation Targeting lipids
CA2763790C (en) 2008-05-30 2016-11-22 Massachusetts Institute Of Technology Compositions and methods for spatial separation and screening of cells
JP2014504295A (ja) 2010-12-17 2014-02-20 アローヘッド リサーチ コーポレイション ｓｉＲＮＡ用ガラクトースクラスター−薬物動態調節剤標的指向部分
US8501930B2 (en) 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
JP5876073B2 (ja) 2010-12-29 2016-03-02 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 核酸の細胞内送達のための小分子複合体
US8916696B2 (en) * 2011-06-12 2014-12-23 City Of Hope Aptamer-mRNA conjugates for targeted protein or peptide expression and methods for their use
RS63244B1 (sr) 2011-12-16 2022-06-30 Modernatx Inc Kompozicije modifikovane mrna
CA2868391A1 (en) * 2012-04-02 2013-10-10 Stephane Bancel Polynucleotides comprising n1-methyl-pseudouridine and methods for preparing the same
EP2885419A4 (en) 2012-08-14 2016-05-25 Moderna Therapeutics Inc ENZYMES AND POLYMERASES FOR RNA SYNTHESIS
LT2922554T (lt) 2012-11-26 2022-06-27 Modernatx, Inc. Terminaliai modifikuota rnr
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
CA2904654C (en) 2013-03-14 2023-12-05 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions and methods of use thereof
ES2797974T3 (es) 2013-03-14 2020-12-04 Translate Bio Inc Acidos ribonucleicos con nucleótidos modificados con 4-tio y procedimientos relacionados
JP6649248B2 (ja) 2013-05-01 2020-02-19 レグルス セラピューティクス インコーポレイテッド 細胞取り込みの向上のための化合物および方法
JP6995478B2 (ja) 2013-05-01 2022-01-14 アイオーニス ファーマシューティカルズ， インコーポレーテッド Ｈｂｖおよびｔｔｒ発現を調節するための組成物および方法
EA201690403A1 (ru) 2013-08-16 2016-07-29 Рана Терапьютикс, Инк. Композиции и способы для модулирования рнк
JP6754997B2 (ja) 2013-08-26 2020-09-16 国立大学法人 東京大学 大環状ペプチド、その製造方法、及び大環状ペプチドライブラリを用いるスクリーニング方法
CN105899666B (zh) * 2014-01-15 2020-10-09 巴斯克立克公司 糖修饰的核酸分子
CN104189897A (zh) * 2014-05-21 2014-12-10 深圳先进技术研究院 一种树突状细胞高效负载抗原的制备方法
SG11201702877TA (en) 2014-10-10 2017-05-30 Hoffmann La Roche Galnac phosphoramidites, nucleic acid conjugates thereof and their use
WO2016118697A1 (en) 2015-01-21 2016-07-28 Phaserx, Inc. Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells
AU2016280709B2 (en) 2015-06-15 2022-09-15 Mpeg La, Llc Defined multi-conjugate oligonucleotides
US10130651B2 (en) 2015-08-07 2018-11-20 Arrowhead Pharmaceuticals, Inc. RNAi Therapy for Hepatitis B Virus Infection
KR20180039726A (ko) 2015-09-04 2018-04-18 더 캘리포니아 인스티튜트 포 바이오메디칼 리써치 인슐린 면역글로불린 융합 단백질
EP3403094A4 (en) 2016-01-15 2019-08-21 Galen Biotechnologies, LLC TRANSFER RNA LIGANDADDUKTBIBLIOTHEKEN
MA45478A (fr) 2016-04-11 2019-02-20 Arbutus Biopharma Corp Compositions de conjugués d'acides nucléiques ciblés
MX2018013919A (es) 2016-06-09 2019-04-15 Curevac Ag Portadores hibridos para cargas de acido nucleico.
EP3551230A1 (en) * 2016-12-08 2019-10-16 CureVac AG Rna for treatment or prophylaxis of a liver disease
EP3574102A4 (en) 2017-01-26 2020-09-30 The Regents of The University of California TARGETED GENE METHYLATION IN PLANTS
CA3056756C (en) 2017-03-17 2021-12-07 Cubicstars, Inc. Method for producing complex of rna molecule and peptide, and utilization thereof
US20200085944A1 (en) * 2017-03-17 2020-03-19 Curevac Ag Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy
EP3461487A1 (en) 2017-09-29 2019-04-03 Nlife Therapeutics S.L. Compositions and methods for the delivery of mrna to hepatic cells
MX2020003995A (es) * 2017-10-19 2020-07-22 Curevac Ag Nuevas moleculas de acido nucleico artificiales.
JP2022500443A (ja) * 2018-09-13 2022-01-04 モデルナティーエックス， インコーポレイテッド 進行性家族性肝内胆汁うっ滞障害を処置するための修飾ｍＲＮＡ
US20220090055A1 (en) 2018-10-24 2022-03-24 Brandeis University Multivalent glycopeptides that tightly bind to carbohydrate-binding monoclonal antibody family pgt128
CN113226332A (zh) 2018-11-02 2021-08-06 阿布特斯生物制药公司 二价靶向缀合物
CN114555621A (zh) 2019-08-15 2022-05-27 Ionis制药公司 键修饰的寡聚化合物及其用途
CN111041025B (zh) 2019-12-17 2021-06-18 深圳市瑞吉生物科技有限公司 基于结合N-乙酰半乳糖胺多肽的mRNA靶向分子及其制备方法
CN112111524B (zh) 2020-01-10 2024-02-27 深圳瑞吉生物科技有限公司 mRNA-GalNAc靶向分子的制备方法及其体内递送系统和应用
CN111235198B (zh) * 2020-01-20 2021-06-15 深圳市瑞吉生物科技有限公司 规模化合成长链rna的方法及其定点修饰的方法
CN111744019B (zh) 2020-07-01 2023-08-04 深圳瑞吉生物科技有限公司 基于甘露糖的mRNA靶向递送系统及其应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Fazhan, W. et al "Optimization of the Linker Length of Mannose-Cholesterol Conjugates for Enhanced mRNA Delivery to Dendritic Cells by Liposomes" Frontiers in Pharmacology, Vol. 9, 2018, Article 980 DOI: 10.3389/fphar.2018.00980 *
JUNG HEESUN; YU GYEONGHUI; MOK HYEJUNG: "CpG oligonucleotide and α-d-mannose conjugate for efficient delivery into macrophages", APPLIED BIOLOGICAL CHEMISTRY, , vol. 59, no. 5, 11 September 2016 (2016-09-11), pages 759 - 763 *

Also Published As

Publication number Publication date
WO2022000884A1 (zh) 2022-01-06
US20230355776A1 (en) 2023-11-09
US20220118099A1 (en) 2022-04-21
CN111744019A (zh) 2020-10-09
EP4008334A4 (en) 2023-03-01
US11707528B2 (en) 2023-07-25
AU2020456532B2 (en) 2023-04-27
AU2020456532A1 (en) 2022-02-03
CN114929244A (zh) 2022-08-19
EP4008334A1 (en) 2022-06-08
CN111744019B (zh) 2023-08-04

Similar Documents

Publication Publication Date Title
AU2020456532B9 (en) Mannose-based mRNA targeted delivery system and use thereof
JP7504464B2 (ja) 核酸ワクチン
RU2769316C2 (ru) Полинуклеотиды, кодирующие интерлейкин-12 (il12), и их применения
JP6990176B2 (ja) メッセンジャーリボ核酸薬物の治療投与のための方法
CN109562192B (zh) 用合成信使rna治疗原发性纤毛运动障碍
WO2020061457A1 (en) Preparation of lipid nanoparticles and methods of administration thereof
CN113939282A (zh) 制备脂质纳米颗粒的方法
AU2016202985A1 (en) Methods of increasing the viability or longevity of an organ or organ explant
CA2923029A1 (en) Chimeric polynucleotides
CN115038788B (zh) mRNA-GalNAc靶向分子的制备方法及其体内递送系统和应用
AU2014337156A1 (en) Compositions and methods for tolerizing cellular systems
CN110201187A (zh) 经修饰的核苷、核苷酸和核酸组合物
EP3987027A1 (en) Endonuclease-resistant messenger rna and uses thereof
WO2024131403A1 (zh) 基于核酸适体的脾脏及其亚细胞的mRNA靶向递送系统
EP4349990A1 (en) Artificial polynucleotides for expressing proteins
EP4356933A1 (en) Composition for delivering modified nucleic acid-containing mrna
KR20240035322A (ko) 변형핵산 함유 mRNA의 체내 전달용 조성물
TW202417629A (zh) 用於改良之多核苷酸轉譯之內部核糖體進入位點
TW202345870A (zh) 具有延長半衰期之信使核糖核酸

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: SHENZHEN RHEGEN BIOTECHNOLOGY CO., LTD.

Free format text: FORMER NAME(S): SHENZHEN RHEGEN BIOMEDICAL TECHNOLOGY CO., LTD.

SREP Specification republished
FGA Letters patent sealed or granted (standard patent)